Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. Gesynta Pharma aims to exploit the full potential of microsomal prostaglandin E synthase-1 (mPGES-1) as a pharmacological target by developing products in areas of unmet medical need where mPGES-1 inhibition provides a clear differentiation. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs.